

Epitope-resolved profiling of the SARS-CoV-2 antibody with endemic human coronaviruses

Cell Reports Medicine

2, 100189

DOI: [10.1016/j.xcrm.2020.100189](https://doi.org/10.1016/j.xcrm.2020.100189)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals. <i>Frontiers in Microbiology</i> , 2020, 11, 618097.	1.5	30
2	COVID-19 Antibody Tests and Their Limitations. <i>ACS Sensors</i> , 2021, 6, 593-612.	4.0	150
3	Variations on a deadly theme: How COVID-19 is changing. <i>Independent Nurse</i> , 2021, 2021, 15-17.	0.0	0
4	Humoral signatures of protective and pathological SARS-CoV-2 infection in children. <i>Nature Medicine</i> , 2021, 27, 454-462.	15.2	137
5	SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 629185.	2.2	42
7	The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic. <i>Frontiers in Immunology</i> , 2021, 12, 637651.	2.2	86
8	A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. <i>Scientific Reports</i> , 2021, 11, 5198.	1.6	55
10	A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. <i>Nature Communications</i> , 2021, 12, 1715.	5.8	138
13	Previous Humoral Immunity to the Endemic Seasonal Alphacoronaviruses NL63 and 229E Is Associated with Worse Clinical Outcome in COVID-19 and Suggests Original Antigenic Sin. <i>Life</i> , 2021, 11, 298.	1.1	23
18	Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development. <i>European Journal of Immunology</i> , 2021, 51, 1839-1849.	1.6	43
19	Review of Current COVID-19 Diagnostics and Opportunities for Further Development. <i>Frontiers in Medicine</i> , 2021, 8, 615099.	1.2	103
22	Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes. <i>Vaccines</i> , 2021, 9, 702.	2.1	5
23	Targeting SARS-CoV-2-Platelet Interactions in COVID-19 and Vaccine-Related Thrombosis. <i>Frontiers in Pharmacology</i> , 2021, 12, 708665.	1.6	15
24	Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern. <i>JCI Insight</i> , 2021, 6, .	2.3	32
25	Production of equine sera as a potential immunotherapy against COVID-19. <i>Investigacion Clinica</i> , 0, 62, 3-17.	0.0	1
26	Antibody and B cell responses to SARS-CoV-2 infection and vaccination. <i>Cell Host and Microbe</i> , 2021, 29, 1063-1075.	5.1	99
27	Dynamics of the Magnitude, Breadth and Depth of the Antibody Response at Epitope Level Following Dengue Infection. <i>Frontiers in Immunology</i> , 2021, 12, 686691.	2.2	5
31	Insights into the virologic and immunologic features of SARS-COV-2. <i>World Journal of Clinical Cases</i> , 2021, 9, 5007-5018.	0.3	3

#	ARTICLE	IF	CITATIONS
32	Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0256482.	1.1	16
33	Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. <i>Cell Reports</i> , 2021, 36, 109604.	2.9	67
34	Optimizing testing regimes for the detection of COVID-19 in children and older adults. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 999-1016.	1.5	14
35	To clot or not to clot? Ad is the question—Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2845-2856.	1.9	16
36	Development of in-house, indirect ELISAs for the detection of SARS-CoV-2 spike protein-associated serology in COVID-19 patients in Panama. <i>PLoS ONE</i> , 2021, 16, e0257351.	1.1	6
37	Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	49
38	Genomic signatures for predicting the zoonotic potential of novel viruses. <i>PLoS Biology</i> , 2021, 19, e3001403.	2.6	6
39	A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 Infection and Its Application in a Population-Based Survey by Mail. <i>Microbiology Spectrum</i> , 2021, 9, e0069321.	1.2	9
40	The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41. <i>International Immunopharmacology</i> , 2021, 101, 108187.	1.7	5
42	Synthetic proteins for COVID-19 diagnostics. <i>Peptides</i> , 2021, 143, 170583.	1.2	5
43	Decomposing the sources of SARS-CoV-2 fitness variation in the United States. <i>Virus Evolution</i> , 2021, 7, veab073.	2.2	14
44	Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. <i>Nature Medicine</i> , 2021, 27, 2002-2011.	15.2	167
45	Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severities. <i>International Journal of Infectious Diseases</i> , 2021, 111, 68-75.	1.5	9
46	Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus. <i>International Immunopharmacology</i> , 2021, 99, 108020.	1.7	14
48	Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses. <i>Infection, Genetics and Evolution</i> , 2021, 95, 105075.	1.0	37
49	Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel. <i>Seminars in Immunology</i> , 2021, 55, 101507.	2.7	16
51	A novel linear and broadly neutralizing peptide in the SARS-CoV-2 S2 protein for universal vaccine development. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2563-2565.	4.8	13
52	Structural Insights on the SARS-CoV-2 Variants of Concern Spike Glycoprotein: A Computational Study With Possible Clinical Implications. <i>Frontiers in Genetics</i> , 2021, 12, 773726.	1.1	3

#	ARTICLE	IF	CITATIONS
54	Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men. <i>Emerging Microbes and Infections</i> , 2021, 10, 2141-2150.	3.0	20
55	Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic. <i>Journal of Molecular Biology</i> , 2022, 434, 167332.	2.0	22
56	Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19. <i>Annals of Internal Medicine</i> , 2022, 175, 119-126.	2.0	13
57	COVID-19 in Africa: preexisting immunity and HIV. <i>Aids</i> , 2021, 35, 2391-2393.	1.0	6
59	Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination. <i>Npj Vaccines</i> , 2021, 6, 132.	2.9	52
60	Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity. <i>Nature Communications</i> , 2021, 12, 6703.	5.8	36
62	BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2. <i>Nature Immunology</i> , 2022, 23, 33-39.	7.0	44
64	Identification of immunodominant epitopes on nucleocapsid and spike proteins of the SARS-CoV-2 in Iranian COVID-19 patients. <i>Pathogens and Disease</i> , 2022, 80, .	0.8	6
65	Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial. <i>Frontiers in Immunology</i> , 2021, 12, 798117.	2.2	42
66	Formation and Expansion of Memory B Cells against Coronavirus in Acutely Infected COVID-19 Individuals. <i>Pathogens</i> , 2022, 11, 186.	1.2	4
67	Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. <i>Cell Host and Microbe</i> , 2022, 30, 83-96.e4.	5.1	64
68	Functional Analysis of Human and Feline Coronavirus Cross-Reactive Antibodies Directed Against the SARS-CoV-2 Fusion Peptide. <i>Frontiers in Immunology</i> , 2021, 12, 790415.	2.2	7
69	IgG Against Human Betacoronavirus Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease Severity. <i>Journal of Infectious Diseases</i> , 2022, 226, 474-484.	1.9	11
70	ELISA-Based Analysis Reveals an Anti-SARS-CoV-2 Protein Immune Response Profile Associated with Disease Severity. <i>Journal of Clinical Medicine</i> , 2022, 11, 405.	1.0	2
72	Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective. <i>Journal of the Indian Institute of Science</i> , 2022, , 1-17.	0.9	12
73	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2022, 14, eabi9215.	5.8	123
75	High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells. <i>Science Immunology</i> , 2022, 7, .	5.6	28
77	Recent Infection With HCoV-OC43 Is Associated With Protection Against Sars-Cov-2 Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
78	The association between contact with children and the clinical course of COVID-19. <i>Epidemiology and Infection</i> , 2022, 150, 1-23.	1.0	1
79	SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. <i>Frontiers in Medicine</i> , 2022, 9, 815389.	1.2	96
80	Severe Acute Respiratory Syndrome Coronavirus 2 Cross-Reactive B and T Cell Responses in Kidney Transplant Patients. <i>Transplantation Proceedings</i> , 2022, 54, 1455-1464.	0.3	3
81	Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2977.	1.8	4
82	Heterologous Immune Responses of Serum IgG and Secretory IgA Against the Spike Protein of Endemic Coronaviruses During Severe COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 839367.	2.2	10
83	Peptide microarrays coupled to machine learning reveal individual epitopes from human antibody responses with neutralizing capabilities against SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2022, 11, 1037-1048.	3.0	10
84	Preclinical Establishment of a Divalent Vaccine against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 516.	2.1	2
86	Microarray-Based Detection of Antibodies against SARS-CoV-2 Proteins, Common Respiratory Viruses and Type I Interferons. <i>Viruses</i> , 2021, 13, 2553.	1.5	15
88	Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	2
89	An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. <i>Science Translational Medicine</i> , 2022, 14, eabn6859.	5.8	31
90	Protein engineering responses to the COVID-19 pandemic. <i>Current Opinion in Structural Biology</i> , 2022, 74, 102385.	2.6	11
92	High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells.. <i>Science Immunology</i> , 2021, , eabl5652.	5.6	6
93	SARS-CoV-2 Virus-like Particles Produced by a Single Recombinant Baculovirus Generate Anti-S Antibody and Protect against Variant Challenge. <i>Viruses</i> , 2022, 14, 914.	1.5	10
94	Structural mapping of antibody landscapes to human betacoronavirus spike proteins. <i>Science Advances</i> , 2022, 8, eabn2911.	4.7	28
96	IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes. <i>Cell Reports</i> , 2022, 39, 110904.	2.9	9
98	Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	21
99	Vaccination with BNT162b2 and ChAdOx1 nCoV-19 Induces Cross-Reactive Anti-RBD IgG against SARS-CoV-2 Variants including Omicron. <i>Viruses</i> , 2022, 14, 1181.	1.5	4
100	COVID-19 vaccination elicits an evolving, cross-reactive antibody response to epitopes conserved with endemic coronavirus spike proteins. <i>Cell Reports</i> , 2022, 40, 111022.	2.9	8

#	ARTICLE	IF	CITATIONS
101	Preexisting Humoral Immunity Cross-Reacting with SARS-CoV-2 Might Prevent Death Due to COVID-19 in Critical Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 3870.	1.0	2
102	SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	57
103	Recent infection with HCoV-OC43 may be associated with protection against SARS-CoV-2 infection. <i>IScience</i> , 2022, 25, 105105.	1.9	11
104	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
106	Covid-19: Early Cases and Disease Spread. <i>Annals of Global Health</i> , 2022, 88, 83.	0.8	3
107	Highly Multiplexed Serology for Nonhuman Mammals. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	1
108	Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity. <i>Gut Microbes</i> , 2022, 14, .	4.3	8
109	Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1 ^β associate with COVID-19 fatal outcome: A cross-sectional analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
110	Cohort profile: S top the Spread Ottawa (SSO) a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination. <i>BMJ Open</i> , 2022, 12, e062187.	0.8	6
111	Comparison of nucleocapsid and spike antibody ELISAs for determining SARS-CoV-2 seropositivity in Kenyan women and infants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	2
112	PepSeq: a fully in vitro platform for highly multiplexed serology using customizable DNA-barcoded peptide libraries. <i>Nature Protocols</i> , 0, , .	5.5	5
113	Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	4
115	SARS-CoV-2 epitopes inform future vaccination strategies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
116	Simultaneous detection of antibody responses to multiple SARS-CoV-2 antigens by a Western blot serological assay. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 8183-8194.	1.7	0
117	Seven classes of antiviral agents. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	8
118	The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. <i>Nature Reviews Immunology</i> , 2023, 23, 304-316.	10.6	56
119	Comparison of one single-antigen assay and three multi-antigen SARS-CoV-2 IgG assays in Nigeria. <i>Journal of Clinical Virology Plus</i> , 2023, 3, 100139.	0.4	0
120	Humoral Immune Response Profile of COVID-19 Reveals Severity and Variant-Specific Epitopes: Lessons from SARS-CoV-2 Peptide Microarray. <i>Viruses</i> , 2023, 15, 248.	1.5	4

#	ARTICLE	IF	CITATIONS
121	Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms. <i>Vaccines</i> , 2023, 11, 58.	2.1	5
122	PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application. <i>Npj Vaccines</i> , 2023, 8, .	2.9	0
123	Seroprevalence of four endemic human coronaviruses and, reactivity and neutralization capability against SARS-CoV-2 among children in the Philippines. <i>Scientific Reports</i> , 2023, 13, .	1.6	6
124	Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
125	Immune Dysregulation in Acute SARS-CoV-2 Infection. <i>Pathogens and Immunity</i> , 2022, 7, 143-170.	1.4	2
126	Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. <i>Vaccines</i> , 2023, 11, 545.	2.1	3
127	Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses. <i>ELife</i> , 0, 12, .	2.8	22
128	Virome-wide detection of natural infection events and the associated antibody dynamics using longitudinal highly-multiplexed serology. <i>Nature Communications</i> , 2023, 14, .	5.8	5
129	Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	15
135	Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation. <i>Chemical Society Reviews</i> , 2023, 52, 6497-6553.	18.7	1
144	PESI: Paratope-Epitope Set Interaction for SARS-CoV-2 Neutralization Prediction. , 2023, , .		0